Among them, 134 were investigating CAR-T therapies for hematological malignancies (targeting mostly CD19 but also BCMA, CD123, CD138, CD16V, CD20, CD22, CD30, CD33, CD70, Ig k, IL-1RAP, Lewis Y, NKG2D ligand, and ROR1), 78 for solid tumors (targeting CEA, c-MET, EGFR, EGFRvIII, EpCAM, EphA2, ErbB2/Her2, FAP, FR-a, GD2, GPC3, IL-13Ra2, L1-CAM, Mesothelin, MUC1, MUC16ecto, PD-L1, PSCA, PSMA, and ROR1), and 9 were long-term follow-up studies [17]. The gene discussed is ERBB2; the disease is hematologic disorder.